Login
Atea Pharmaceuticals, Inc. logo

Atea Pharmaceuticals, Inc.

ateapharma.com

What Do They Do?

Develops oral antiviral drug candidates for hepatitis C and hepatitis E infections.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▲ +24% (Loss)
vs −$42M in Q3 FY2025

From coronavirus to hepatitis The older report centered on bemnifosbuvir for coronavirus disease. The latest report focuses on hepatitis C and hepatitis E candidates and says the company stopped developing bemnifosbuvir for coronavirus disease after its trial missed its primary endpoint.

Who Do They Compete With?

Competes with Gilead Sciences, AbbVie, and Merck

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support